ATE389016T2 - Sirna knockout prüfverfahren und konstrukte - Google Patents

Sirna knockout prüfverfahren und konstrukte Download PDF

Info

Publication number
ATE389016T2
ATE389016T2 AT02776950T AT02776950T ATE389016T2 AT E389016 T2 ATE389016 T2 AT E389016T2 AT 02776950 T AT02776950 T AT 02776950T AT 02776950 T AT02776950 T AT 02776950T AT E389016 T2 ATE389016 T2 AT E389016T2
Authority
AT
Austria
Prior art keywords
sequence
rna
polynucleotides
complementary
vectors
Prior art date
Application number
AT02776950T
Other languages
English (en)
Inventor
Gert-Jan Arts
Ellen Langemeijer
Ivo Piest
Es Helmuth Van
Godefridus Michiels
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26980845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE389016(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galapagos Nv filed Critical Galapagos Nv
Application granted granted Critical
Publication of ATE389016T2 publication Critical patent/ATE389016T2/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C12N2330/31—Libraries, arrays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Peptides Or Proteins (AREA)
AT02776950T 2001-09-01 2002-08-29 Sirna knockout prüfverfahren und konstrukte ATE389016T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31722901P 2001-09-01 2001-09-01
US38573302P 2002-06-04 2002-06-04

Publications (1)

Publication Number Publication Date
ATE389016T2 true ATE389016T2 (de) 2008-03-15

Family

ID=26980845

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02776950T ATE389016T2 (de) 2001-09-01 2002-08-29 Sirna knockout prüfverfahren und konstrukte

Country Status (8)

Country Link
US (2) US20030198627A1 (de)
EP (1) EP1444346B2 (de)
JP (1) JP2005501557A (de)
AT (1) ATE389016T2 (de)
AU (1) AU2002339458A1 (de)
CA (1) CA2457419A1 (de)
DE (1) DE60225586T3 (de)
WO (1) WO2003020931A2 (de)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
GB9925459D0 (en) * 1999-10-27 1999-12-29 Plant Bioscience Ltd Gene silencing
DE10100586C1 (de) * 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US20030084471A1 (en) * 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
EP1272630A2 (de) 2000-03-16 2003-01-08 Genetica, Inc. Methoden und zusammensetzungen zur interferenz durch rna
US8202846B2 (en) 2000-03-16 2012-06-19 Cold Spring Harbor Laboratory Methods and compositions for RNA interference
US7423142B2 (en) * 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US7767802B2 (en) * 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
IL159756A0 (en) 2001-07-12 2004-06-20 Univ Massachusetts IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING
EP1281767A3 (de) 2001-07-31 2003-05-28 Aladar A. Szalay Lichtausstrahlende Mikroorganismen und Zellen für die Diagnose und Therapie von Tumoren
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
DE10163098B4 (de) 2001-10-12 2005-06-02 Alnylam Europe Ag Verfahren zur Hemmung der Replikation von Viren
DE10230997A1 (de) * 2001-10-26 2003-07-17 Ribopharma Ag Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels
US20040121348A1 (en) * 2001-10-26 2004-06-24 Ribopharma Ag Compositions and methods for treating pancreatic cancer
WO2003046186A1 (fr) * 2001-11-28 2003-06-05 Toudai Tlo, Ltd. Systeme d'expression d'arnsi et procede de production de cellule knockdown a gene fonctionnel ou analogue utilisant ce systeme
GB0130955D0 (en) * 2001-12-24 2002-02-13 Cancer Res Ventures Expression system
DE10202419A1 (de) * 2002-01-22 2003-08-07 Ribopharma Ag Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
ATE407138T1 (de) * 2002-02-14 2008-09-15 Hope City Verfahren zur herstellung interferierender rna- moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
WO2003093441A2 (en) 2002-05-03 2003-11-13 Duke University A method of regulating gene expression
AU2003239851A1 (en) * 2002-05-08 2003-11-11 Xantos Biomedicine Ag Expression constructs for producing double-stranded (ds) rna and the use thereof
US20030228261A1 (en) * 2002-06-05 2003-12-11 Aladar Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
EP1369491A1 (de) 2002-06-05 2003-12-10 Aladar A. Szalay Lichtemittierende Mikroorganismen und Zellen für die Diagnose und Therapie von Krankheiten assoziiert mit Wunden oder entzündetem Gewebe
JP2006500023A (ja) * 2002-09-20 2006-01-05 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ランダムＲＮＡｉライブラリーの生成法、および細胞に基づくスクリーニングにおける該ライブラリーの適用
US7892793B2 (en) 2002-11-04 2011-02-22 University Of Massachusetts Allele-specific RNA interference
US20060135453A1 (en) * 2003-01-31 2006-06-22 Jean-Charles Bologna Down-regulation of target-gene with pei/single-stranded oligoribonucleotide complexes
AU2003224132A1 (en) * 2003-04-24 2004-11-19 Galapagos Genomics N.V. Effective sirna knock-down constructs
US7524653B2 (en) * 2003-05-09 2009-04-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Small interfering RNA libraries and methods of synthesis and use
ATE485394T1 (de) 2003-06-02 2010-11-15 Univ Massachusetts Verfahren und zusammensetzungen zur verbesserung der wirksamkeit und spezifität von fnai
US7750144B2 (en) 2003-06-02 2010-07-06 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of RNA silencing
US7459547B2 (en) 2003-06-02 2008-12-02 University Of Massachusetts Methods and compositions for controlling efficacy of RNA silencing
RU2376371C2 (ru) 2003-06-18 2009-12-20 Дженелюкс Корпорейшн Модифицированные рекомбинантные вакцинирующие вирусы и другие микроорганизмы и их применение
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US8680063B2 (en) 2003-09-12 2014-03-25 University Of Massachusetts RNA interference for the treatment of gain-of-function disorders
US20060134787A1 (en) 2004-12-22 2006-06-22 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
WO2005063983A1 (en) * 2003-12-29 2005-07-14 Galapagos Genomics N.V. Modulators of bone homeostasis identified in a high-throughput screen
PT1733056E (pt) 2004-03-31 2013-08-29 Gen Hospital Corp Método para determinar a responsividade do cancro a tratamentos visando o receptor do factor de crescimento epidérmico
DK1745295T3 (da) 2004-04-20 2011-01-31 Galapagos Nv Fremgangsmåder, sammensætninger og forbindelsesanalyser til hæmning af produktionen af amyloid beta-protein
MXPA06012162A (es) 2004-04-27 2007-03-30 Galapagos Nv Metodos, agentes y ensayos de seleccion de compuestos para inducir diferenciacion de celulas de mamifero no diferenciadas, en osteoblastos.
EP2290072B1 (de) 2004-05-28 2014-12-17 Asuragen, Inc. Verfahren und Zusammensetzungen mit MicroRNA
EP1773997B1 (de) 2004-06-14 2011-11-23 Galapagos N.V. Identifizierungsverfahren und verbindungen für die behandlung degenerativer und entzündlicher erkrankungen
US20070004658A1 (en) 2004-06-21 2007-01-04 Nick Vandeghinste Method and means for treatment of osteoarthritis
WO2006006520A1 (ja) * 2004-07-09 2006-01-19 Genofunction, Inc. 新規創薬標的の探索方法
US7485468B2 (en) * 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
US8673268B2 (en) 2004-10-15 2014-03-18 Galapagos N.V. Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
ES2534304T3 (es) 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
SG162726A1 (en) * 2005-05-27 2010-07-29 San Raffaele Centro Fond Gene vector comprising mi-rna
US7919583B2 (en) 2005-08-08 2011-04-05 Discovery Genomics, Inc. Integration-site directed vector systems
WO2007022470A2 (en) 2005-08-18 2007-02-22 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating neurological disease
CA2644995A1 (en) * 2006-03-07 2007-09-13 The Trustees Of The University Of Pennsylvania Random rnai libraries, methods of generating same, and screening methods utilizing same
AU2014202015B2 (en) * 2006-03-07 2016-06-02 The Trustees Of The University Of Pennsylvania Random RNAi libraries, methods of generating same, and screening methods utilizing same
FR2898908A1 (fr) 2006-03-24 2007-09-28 Agronomique Inst Nat Rech Procede de preparation de cellules aviaires differenciees et genes impliques dans le maintien de la pluripotence
AU2007253677B2 (en) * 2006-05-22 2011-02-10 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of IKK-B gene
WO2007147067A2 (en) * 2006-06-14 2007-12-21 Rosetta Inpharmatics Llc Methods and compositions for regulating cell cycle progression
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
JP2008086201A (ja) * 2006-09-29 2008-04-17 Gifu Prefecture Kenkyu Kaihatsu Zaidan マイクロｒｎａ生成の検出方法と癌の診断・治療およびマイクロｒｎａ生成調整剤
WO2008100292A2 (en) 2006-10-16 2008-08-21 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
US8114982B2 (en) * 2006-12-06 2012-02-14 Albert Einstein College Of Medicine Of Yeshiva University Multi-microRNA methods and compositions
WO2008156655A2 (en) 2007-06-15 2008-12-24 Genelux Corporation Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
EP2162747B1 (de) 2007-06-20 2014-04-30 Galapagos N.V. Molekulaire targets und verfahren zur identifikation von substanzen für die behandlung von degenerativen knochen- und gelenkserkrankungen
US8841437B2 (en) * 2008-06-20 2014-09-23 The Board Of Trustees Of The Leland Stanford Junior University Precursor miRNA loop-modulated target regulation
JP4517096B2 (ja) * 2007-07-17 2010-08-04 愛知県 癌の遺伝子治療ベクター及び癌治療用医薬組成物
EP2198050A1 (de) 2007-09-14 2010-06-23 Asuragen, INC. Mikrornas mit unterschiedlicher expression bei zervikalkarzinom und verwendungen davon
WO2009054996A2 (en) * 2007-10-25 2009-04-30 Genelux Corporation Systems and methods for viral therapy
US8258111B2 (en) 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
JP5763530B2 (ja) * 2008-06-10 2015-08-12 サンガモ バイオサイエンシーズ， インコーポレイテッド Ｂａｘ−およびＢａｋ−欠損細胞株の生成のための方法および組成物
WO2010008562A2 (en) 2008-07-16 2010-01-21 Recombinetics Methods and materials for producing transgenic animals
WO2010029118A1 (en) 2008-09-11 2010-03-18 Biofocus Dpi B.V. Method for identifying compounds useful for increasing the functional activity and cell surface expression of cf-associated mutant cystic fibrosis transmembrane conductance regulator
WO2010094732A1 (en) 2009-02-19 2010-08-26 Biofocus Dpi B.V. Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
EP2398479A2 (de) 2009-02-19 2011-12-28 Galapagos N.V. Verfahren zur identifizierung und verbindungen zur diagnose und behandlung von mit entzündung einhergehenden krankheiten
US20110306655A1 (en) 2009-02-19 2011-12-15 Richard Antonius Jozef Janssen Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
WO2010115825A2 (en) 2009-03-31 2010-10-14 Robert Zimmermann Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
WO2010112569A1 (en) 2009-03-31 2010-10-07 Robert Zimmermann Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
WO2010115841A1 (en) 2009-04-01 2010-10-14 Galapagos Nv Methods and means for treatment of osteoarthritis
WO2011015573A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
WO2011015572A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
TW201120043A (en) 2009-11-05 2011-06-16 Galapagos Nv Fused pyrazine compounds as their salts, useful for the treatment of degenerative and inflammatory diseases
JP2013510564A (ja) 2009-11-13 2013-03-28 パンガエア ビオテック、ソシエダッド、リミターダ 肺癌におけるチロシンキナーゼ阻害剤に対する応答を予測するための分子バイオマーカー
US20130183326A9 (en) 2009-11-20 2013-07-18 St. Jude Children's Research Hospital Methods and compositions for modulating the activity of the interleukin-35 receptor complex
TW201129365A (en) * 2010-02-05 2011-09-01 Hoffmann La Roche Compositions and methods for inhibiting expression of IKK2 genes
JP5794558B2 (ja) * 2010-03-24 2015-10-14 国立研究開発法人産業技術総合研究所 改変された致死遺伝子及び該遺伝子を含むベクター
US8383793B2 (en) 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
ES2699630T3 (es) * 2010-04-23 2019-02-12 Cold Spring Harbor Laboratory Novedosos ARNhc diseñados estructuralmente
EP2851426B1 (de) 2010-10-18 2018-08-22 Arrowhead Pharmaceuticals, Inc. Zusammensetzungen und Verfahren zur Hemmung der Expression von RRM2-Genen
EP2468883A1 (de) 2010-12-22 2012-06-27 Pangaea Biotech S.L. Molekulare Biomarker zur Vorhersage der Reaktion auf Tyrosinkinaseinhibitoren bei Lungenkrebs
EP2492688A1 (de) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Molekulare Biomarker zur Vorhersage der Reaktion auf die Antitumorbehandlung bei Lungenkrebs
US20140157443A1 (en) 2011-04-14 2014-06-05 St. Jude Children's Research Hospital Methods and compositions for detecting and modulating a novel mtor complex
CA2836299A1 (en) 2011-04-15 2012-10-18 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
SG194751A1 (en) 2011-06-30 2013-12-30 Arrowhead Res Corp Compositions and methods for inhibiting gene expression of hepatitis b virus
US9644241B2 (en) 2011-09-13 2017-05-09 Interpace Diagnostics, Llc Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
US20140087362A1 (en) 2012-03-16 2014-03-27 Aladar A. Szalay Methods for assessing effectiveness and monitoring oncolytic virus treatment
US20130280170A1 (en) 2012-04-20 2013-10-24 Aladar A. Szalay Imaging methods for oncolytic virus therapy
WO2013190089A1 (en) 2012-06-21 2013-12-27 Pangaea Biotech, S.L. Molecular biomarkers for predicting outcome in lung cancer
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
EP3279316B1 (de) 2012-11-20 2023-09-20 Phytoplant Research, S.L.U. Obere Pyramidenmotoneuronen, Verfahren und Zusammensetzungen zur Unterscheidung neuraler Stammzellen durch Modulation der CB1-Cannabinoidrezeptor-Signalisierung und Verwendungen davon
WO2014139884A2 (en) 2013-03-14 2014-09-18 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrosis
JP2016522675A (ja) 2013-03-14 2016-08-04 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． 上皮間葉移行に関連した疾患の治療において有用な分子標的及び前記標的のインヒビター
EP2972322B1 (de) 2013-03-14 2019-03-06 Galapagos NV Zielmoleküle und -verbindungen, und verfahren zur identifikation davon, zur behandlung von fibrotischen erkrankungen
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
US11332719B2 (en) * 2013-03-15 2022-05-17 The Broad Institute, Inc. Recombinant virus and preparations thereof
IL289396B2 (en) 2013-03-15 2023-12-01 The General Hospital Coporation Using truncated guide rnas (tru-grnas) to increase specificity for rna-guided genome editing
EP2813571A1 (de) 2013-06-13 2014-12-17 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Verfahren zur Behandlung von Lungenkrebs
WO2015051366A2 (en) 2013-10-04 2015-04-09 Novartis Ag Novel formats for organic compounds for use in rna interference
EP3052464B1 (de) 2013-10-04 2020-04-15 Novartis AG 3 endkappen für rnai-mittel zur verwendung in der rna-interferenz
CN105792832B (zh) 2013-10-04 2021-03-23 诺华股份有限公司 用于治疗乙肝病毒的有机化合物
EP3090044B1 (de) * 2013-12-26 2021-11-03 The General Hospital Corporation Multiplex-führungs-rnas
WO2015134528A1 (en) * 2014-03-04 2015-09-11 Donald Danforth Plant Science Center New generation of artificial micrornas
CN107206088A (zh) 2014-12-05 2017-09-26 豪夫迈·罗氏有限公司 使用pd‑1轴拮抗剂和hpk1拮抗剂用于治疗癌症的方法和组合物
WO2017027350A2 (en) 2015-08-07 2017-02-16 Arrowhead Pharmaceuticals, Inc. Rnai therapy for hepatitis b virus infection
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
JOP20190015A1 (ar) 2016-08-04 2019-02-04 Arrowhead Pharmaceuticals Inc عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
CN109456995A (zh) * 2018-11-08 2019-03-12 杜以军 基因敲除质粒、细胞系及制备方法和应用
US20220356529A1 (en) 2019-07-16 2022-11-10 Université Cote D'azur Method of assessing the sensitivity or resistance of a subject to an oncolytic virus, recombinant virus, preparation and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US6060456A (en) * 1993-11-16 2000-05-09 Genta Incorporated Chimeric oligonucleoside compounds
US6146886A (en) * 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
WO1996029097A1 (en) * 1995-03-21 1996-09-26 Research Corporation Technologies, Inc. Stem-loop and circular oligonucleotides
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
EP2267138B1 (de) † 1998-04-08 2016-06-08 Commonwealth Scientific and Industrial Research Organization Verfahren und Mittel zum Erhalt von modifizierten Phänotypen
US6413776B1 (en) * 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
AU775679B2 (en) * 1998-08-20 2004-08-12 Cell Genesys, Inc. Use of suppressor tRNA's to regulate cytotoxicity during the production of recombinant gene products
WO2000049035A1 (en) * 1999-02-19 2000-08-24 The General Hospital Corporation Gene silencing
GB9904905D0 (en) * 1999-03-03 1999-04-28 Oxford Biomedica Ltd Cells
US6326193B1 (en) * 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
PT1309726E (pt) * 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
US20020132788A1 (en) * 2000-11-06 2002-09-19 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
KR100909681B1 (ko) * 2000-12-01 2009-07-29 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
US6399378B1 (en) * 2001-03-01 2002-06-04 Isis Pharmaceuticals, Inc. Antisense modulation of RECQL2 expression
GB0118223D0 (en) * 2001-07-26 2001-09-19 Univ Sheffield Stem loop RNA
US20030148519A1 (en) * 2001-11-14 2003-08-07 Engelke David R. Intracellular expression and delivery of siRNAs in mammalian cells
US20040053876A1 (en) * 2002-03-26 2004-03-18 The Regents Of The University Of Michigan siRNAs and uses therof

Also Published As

Publication number Publication date
US20050214851A1 (en) 2005-09-29
CA2457419A1 (en) 2003-03-13
DE60225586T3 (de) 2015-12-03
AU2002339458A1 (en) 2003-03-18
WO2003020931A2 (en) 2003-03-13
EP1444346A2 (de) 2004-08-11
DE60225586T2 (de) 2009-04-02
US20030198627A1 (en) 2003-10-23
EP1444346B1 (de) 2008-03-12
JP2005501557A (ja) 2005-01-20
WO2003020931A3 (en) 2003-11-20
DE60225586D1 (de) 2008-04-24
EP1444346B2 (de) 2015-06-24

Similar Documents

Publication Publication Date Title
ATE389016T2 (de) Sirna knockout prüfverfahren und konstrukte
Sklenár̆ et al. Formation of a stable triplex from a single DNA strand
TR200700740T2 (tr) Nogo genlerinin nükleotid ve protein dizileri ve bunlar bazında yöntemler
WO2002031134A3 (en) Novel serine protease genes related to dppiv
WO2003089598A3 (en) Polypeptides having xyloglucanase activity and nucleic acids encoding same
ATE531729T1 (de) Kdr-peptide und diese enthaltende impfstoffe
WO2004006838A3 (en) Novel kinases
DK0917571T3 (da) Hidtil ukendt agoutirelateret gen
ATE443074T1 (de) Zubereitungen und methoden zur verwendung in rekombinatorischem klonen von nukleinsäuren
IL174902A (en) Non-neutralized and multi-specific 3cd binders, nucleic acid sequence encoding them, process for their preparation, preparation, kit, vector, surrogate cell and their use
WO2000073469A3 (en) Protein kinases
WO2001083782A3 (en) Novel proteases
WO2005000200A3 (en) Novel kinases
HUP9800329A2 (hu) Nukleinsavkonstrukciók strukturális gének sejtciklus-függő módon szabályozott expresszálására
WO1999066051A3 (en) Nek-related and bub1-related protein kinases
EP1549760A4 (de) Sak: modulation der zellproliferation zur krebsbehandlung
WO2004096976A3 (en) Spex compositions and methods of use
WO2000047723A3 (en) Human diacylglycerol kinase beta (hdagk beta) proteins and nucleotide sequences encoding the same
WO2001036478A3 (en) Methods and compositions relating to bactericidal/permeability increasing factor-like polypeptides and polynucleotides
ATE459643T1 (de) Ee3-proteinfamilie und zugrundeliegende dna- sequenzen
AU7645400A (en) Polypeptides having glucanotransferase activity and nucleic acids encoding same
WO2002077009A3 (en) Polypeptides having gamma-glutamyl transpeptidase activity and nucleic acids encoding same
JPH09154585A (ja) マイクロ遺伝子のランダム重合体作成方法
HK1043155A1 (zh) 噬菌體t4基因35的基因及蛋白質排列
EP1524275A3 (de) De-immunisierte Bindungsmoleküle für CD3

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1444346

Country of ref document: EP